Table 7.
SARS-CoV-2 Infection | p | |||||
---|---|---|---|---|---|---|
Yes | No | |||||
n= 140 | n = 767 | |||||
Adverse reactions after vaccination | Not | 101 | 72% | 459 | 60% | 0.004 |
Yes | 39 | 28% | 308 | 40% | ||
Type of adverse reactions | Pain | 112 | 80% | 539 | 70% | 0.027 |
Swelling at the injection site | 25 | 18% | 46 | 6% | <0.001 | |
Redness at the injection site | 13 | 9% | 43 | 6% | 0.148 | |
Pruritus at the injection site | 3 | 2% | 19 | 2% | 0.962 | |
Fatigue | 42 | 30% | 112 | 15% | <0.001 | |
Poor well-being | 39 | 28% | 69 | 9% | <0.001 | |
Shivers | 24 | 17% | 34 | 4% | <0.001 | |
Fever | 18 | 13% | 18 | 2% | <0.001 | |
Muscle and joint pain | 30 | 21% | 61 | 8% | <0.001 | |
Headache | 21 | 15% | 48 | 6% | <0.001 | |
Nausea/vomiting | 9 | 6% | 13 | 2% | 0.002 | |
Diarrhoea | 3 | 2% | 5 | 1% | 0.218 | |
Enlargement of lymph nodes | 11 | 8% | 8 | 1% | <0.001 | |
Insomnia | 4 | 3% | 3 | 0% | 0.011 | |
Acute peripheral facial nerve palsy | 0 | - | 2 | 0% | 0.711 | |
Allergic reaction | 2 | 1% | 2 | 0% | 0.224 | |
Anaphylaxis/anaphylactic shock requiring the administration of adrenaline | 0 | - | 0 | - | 1.0000 |
Abbreviations: ‘-’—lack of data.